Basaglar Sales Level Off For Lilly
Second-Quarter Sales Stagnant, While First-Half Turnover Is Up By A Tenth
Eli Lilly has seen sales of its Basaglar insulin glargine hybrid remain static in the second quarter of 2020. However, the company reported total sales for the first half that were up by a tenth compared to the first half of 2019.